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Introduction {#sec1}
============

The *Enterovirus B* (EV-B) group consists of echovirus, coxsackievirus B (CV-B), coxsackievirus A9 (CV-A9), and other newly identified enteroviruses ([@bib37]). EV-B infections cause viral encephalitis (VE), viral meningitis (VM), and viral meningo-encephalitis (VME), leading to substantial morbidity and mortality in children ([@bib26], [@bib31]). They are also the causative agents of acute flaccid paralysis (AFP), nonspecific rashes, pneumonitis, hepatitis, coagulopathy, and hand-foot-and-mouth disease (HFMD) ([@bib2], [@bib27]). In recent years, severe outbreaks of echovirus infections have been documented in America, Europe, and Asia ([@bib16], [@bib30], [@bib32], [@bib35]). In particular, echoviruses and CV-A9 accounted for seven out of the top 15 most frequently occurring enterovirus serotypes from 2014--2016 in the United States ([@bib1]). In China, surveillance of children with VE and VM in several provinces revealed that EV-B, especially echovirus, is the dominant serotype in the cerebrospinal fluid of patients ([@bib13], [@bib78]). It remains obscure how EV-B viruses cross the blood-brain barrier to cause these neurological diseases. Thus, discovery of their potential receptor(s) and entry mechanism will provide insight into the underling mechanisms of EV-B crossing the blood-brain barrier.

According to our current understanding, there are two types of receptors, attachment and uncoating receptors, that are involved in non-enveloped virus entry and genome release ([@bib50]). However, their differential roles remain undetermined. To date, several host receptors have been identified to facilitate the entry of enteroviruses, including CD155 (PVR) for poliovirus, intercellular adhesion molecule-1 (ICAM-1) for CV-A21 and CV-A24, scavenger receptor B2 (SCARB2) and P-selectin glycoprotein ligand-1 (PSGL-1) for EV-A71, and KREMEN1 for some of the group A enteroviruses ([@bib2], [@bib4], [@bib39], [@bib40], [@bib56], [@bib63], [@bib69], [@bib71]). For EV-B, CD55 has previously been reported as the receptor for CV-B1, -B3, -B5 and several other echovirus serotypes. Moreover, α~2~β~1~ integrin is the receptor for Echo 1, while α~V~β~6~ and α~V~β~3~ integrins facilitate CV-A9 entry ([@bib6], [@bib7], [@bib24], [@bib65], [@bib68]). Among the above EV-B receptors, CD55, α~2~β~1~, α~V~β~6~, and α~V~β~3~ are responsible for virus attachment, but none of them induce conformational changes in the viral particle, a process required for virus uncoating and genome release ([@bib55], [@bib63]). Although coxsackie and adenovirus receptor (CAR) serves as the uncoating receptor for CV-B ([@bib8]), the uncoating receptors for other EV-B viruses are yet unknown.

Capsid uncoating and genome release are critical steps to fulfill the life cycle of non-enveloped virus after its attachment ([@bib50]). Interestingly, most of the identified uncoating receptors for picornavirus (e.g., PVR, CAR, and ICAM-1) are Ig-like proteins ([@bib8], [@bib22], [@bib50]), with the exception of SCARB2 ([@bib64]). Most of the uncoating receptors bind to the "canyon" sites (deep depressions surrounding the five-fold axis) of the viral particle ([@bib50]). This binding triggers the release of "pocket factor," which is hypothesized to be a lipid accommodated within a pocket below the canyon to stabilize the virion structure, and subsequently induces conformational changes in the viral particle ([@bib5], [@bib50]). The general concepts for enterovirus entry have previously been established using cryo-electron microscopy (cryo-EM) structures of several enteroviruses in complexes with their receptors at moderate resolutions, including poliovirus, CV-B3, CV-A21, and CV-A24 ([@bib4], [@bib11], [@bib23], [@bib42], [@bib58], [@bib70], [@bib74]). However, structural information of enterovirus-receptor complexes at atomic resolution and the mechanism of "pocket factor" release are missing, which would provide a much more accurate and systematic insight into the process of enterovirus entry.

Here, we identified neonatal Fc receptor (FcRn) as a universal uncoating receptor for a large group of EV-B viruses by CRISPR-Cas9 library screening. As an immune factor, FcRn is hijacked by the virus as its uncoating receptor. FcRn-mediated uncoating was confirmed by FcRn-decorated liposome experiments. We also determined a series of high-resolution cryo-EM structures of Echo 6 virus in the apo form and in complex with either its attachment receptor CD55 or uncoating receptor FcRn, at both neutral and acidic pH conditions. By comparing these structures, we systematically dissected the differential roles of Echo 6 attachment and uncoating receptors. It is the uncoating receptor FcRn that triggers the "pocket factor" release at a low pH within the endosome.

Results {#sec2}
=======

FcRn Is a Functional Receptor for Echo 6 Infection {#sec2.1}
--------------------------------------------------

To identify the uncoating receptor for EV-B viruses, we performed a CRISPR knockout screen with Echo 6 strain SJZ-366 ([@bib13]) in the RD-Cas9 cell line using a focused single guide RNA (sgRNA) library featuring human membrane protein-encoding genes. The sgRNA-coding regions were amplified from the extracted genomic DNA of library cells before and after Echo 6 infection, followed by next-generation sequencing (NGS) and data analysis using the MAGeCK method ([@bib43], [@bib77], [@bib79]) ([Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc2){ref-type="supplementary-material"}). The top genes from the screen were: *CD55*, which has already been identified to encode the known Echo 6 receptor responsible for virus attachment ([@bib7], [@bib65]); and *FCGRT* and *B2M*, encoding two subunits of FcRn, respectively ([Figures 1](#fig1){ref-type="fig"}A and 1B). FcRn is an MHC class I-like protein consisting of a heavy α chain encoded by the *FCGRT* gene, and a light β2-microglubulin (β2 m) chain encoded by the *B2M* gene. The α chain of FcRn contains three domains (α1, α2, and α3). The α3 and β2 m domains adopt immunoglobulin (Ig)-like folds ([@bib41]) ([Figure S1](#figs1){ref-type="fig"} A).Figure 1CRISPR Screening Uncovered FcRn, a Functional Receptor for Echo 6 Infection(A) Dot plot illustrating the enriched genes from the CRISPR screen. Genes were rank-ordered by robust rank aggregation (RRA) scores based on MAGeCK analysis. The height and size of the top three genes, differently colored, was proportional to their RRA scores.(B) Schematic diagram of sgRNA library construction and Echo 6 receptor screening.(C and G) Echo 6 infection in *FCGRT*^KO^, *B2M*^KO^, *CD55*^KO^, and wild type (WT) HEK293T cells (C). Echo 6 infection in *CD55*^KO^ (G), with the above three cell lines in (C) as controls. TCID~50~ was calculated at 48 h post infection (h.p.i). "+" and "-" indicate the presence or absence of FcRn or CD55 in the KO cell lines.(D and E) Echo 6 infection in *FCGRT*^KO^ cells complemented with lentivirus expressing FCGRT (D) and *B2M*^KO^ cells complemented with lentivirus expressing β2 m (E). KO cell lines with lentivirus expressing GFP was used as a control. Cells were infected with Echo 6 (MOI 0.01), and supernatants were harvested for virus titration at 24 h.p.i.(F) Light microscopy images showing CPE of *FCGRT*^KO^, *B2M*^KO^, *CD55*^KO^, and WT HEK293T cells at 24 h.p.i with Echo 6 (MOI 1). Immunofluorescence images of KO and WT cells infected by Echo 6 (MOI 10) for 8 h and then stained by anti-Echo 6 antibodies. The scale bar represents 50 μm.(H) Growth curve of Echo 6 in *FCGRT*^KO^, *B2M*^KO^, *CD55*^KO^, and WT HEK293T cells.(I) Echo 6 was inoculated onto non-susceptible CHO (left) and BHK (right) cells with ectopic expression of human FcRn (FCGRT+β2 m), CD55, or both.The data depict means with SEM. TCID~50~ values were calculated by the Reed-Muench method. Experiments were repeated three times. \# stands for undetected; ^∗∗∗∗^p \< 0.0001; ns, not significant.See also [Figures S1](#figs1){ref-type="fig"} and [S2](#figs2){ref-type="fig"} and [Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc2){ref-type="supplementary-material"}.Figure S1*FCGRT* or *B2M* KO Has No Effect on CD55 Expression, Related to [Figure 1](#fig1){ref-type="fig"}(A) Diagram of FcRn. The α chain expressed by *FCGRT* contains a transmembrane domain and three extracellular domains (α1, α2 and α3). The β2 m chain is expressed by *B2M*.(B) Sanger sequencing of *FCGRT, B2M* and *CD55* in KO cells. Sequencing data shows an alignment of WT sequence with the KO sequence.(C) western blot of CD55 expression in WT, *FCGRT*^KO^, *B2M*^KO^ and *CD55*^KO^ cells.(D) Flow cytometry analysis of CD55 expression in WT, *FCGRT*^KO^, *B2M*^KO^ (left panel: fixed cell staining, middle panel: cell surface expression) and *CD55*^KO^ cells (right panel).

To verify FcRn's role in echovirus infection, we infected *FCGRT* ^KO^ and *B2M* ^KO^ HEK293T cell lines with Echo 6 virus ([Figure S1](#figs1){ref-type="fig"}B). Cytopathic effect (CPE) was undetectable in either *FCGRT* ^KO^ or *B2M* ^KO^ HEK293T cells ([Figures 1](#fig1){ref-type="fig"}C and 1F, upper two panels). No Echo 6-positive signals were observed in either *FCGRT* ^KO^ or *B2M* ^KO^ HEK293T cells by immunofluorescence staining ([Figure 1](#fig1){ref-type="fig"}F, lower two panels), and no obvious viral replication was observed for both knockout (KO) cell lines spanning a 60-h growth ([Figure 1](#fig1){ref-type="fig"}H). Moreover, exogenous expression of the corresponding genes restored the susceptibility of both gene knockout lines to Echo 6 infection ([Figures 1](#fig1){ref-type="fig"}D, 1E, and [S2](#figs2){ref-type="fig"} A--S2D). Furthermore, ectopic expression of human FcRn enabled efficient Echo 6 infection in two non-permissive cells, CHO and BHK ([@bib47]) ([Figures 1](#fig1){ref-type="fig"}I and [S2](#figs2){ref-type="fig"}E--S2I).Figure S2FcRn Complementation Can Restore Susceptibility; Ectopic Expression Makes Non-permissive Cells Susceptible to Echovirus, Related to [Figure 1](#fig1){ref-type="fig"}(A and B) western blot of FCGRT (A) and β2 m (B) expression in WT, KO and supplementary cells.(C and D) qPCR analysis of Echo 6 infection in *FCGRT*^KO^ cells complemented with lentivirus expressing FCGRT (C). *B2M*^KO^ cells complemented with lentivirus expressing β2 m (D). KO cell lines with lentivirus expressing GFP were used as a control. Cells were infected with 0.01 MOI Echo 6, and supernatants were taken for virus titration after 24 h.(E and F) western blot of FCGRT and CD55 expression in WT, human FcRn, human CD55 and human FcRn+ CD55 ectopic expression CHO (E) or BHK (F) cells.(G and H) qPCR analysis of Echo 6 in non-susceptible CHO (G) and BHK (H) cells with ectopic expression of human FcRn (FCGRT+B2M), CD55 or both.(I) Echovirus infection in CHO cells with the ectopic expression of FCGRT only. (The data depict means with SEM. C, D, G and H: one-way ANOVA with multiple comparisons; I: unpaired two-tailed t test, with a Welch post-correction. \# stands for undetected. ^∗∗∗∗^p \< 0.0001; and ns, not significant.)

Importantly, knockout of neither *FCGRT* nor *B2M* downregulated CD55 expression ([Figures S1](#figs1){ref-type="fig"}C and S1D). As expected, *CD55* ^KO^ reduced Echo 6 infection ([Figure 1](#fig1){ref-type="fig"}G), however, *CD55* ^KO^ cells, different from *FCGRT* ^KO^ and *B2M* ^KO^ cells, were still permissive for virus infection ([Figures 1](#fig1){ref-type="fig"}F and 1G). Despite delayed viral growth kinetics, Echo 6 could eventually reach high titers in *CD55* ^KO^ cells ([Figure 1](#fig1){ref-type="fig"}H).

FcRn Is Essential for Major Serotypes of EV-Bs {#sec2.2}
----------------------------------------------

Echo 6 belongs to the EV-B group, which includes echoviruses, CV-Bs, CVA-9, and several newly identified enterovirus serotypes ([Figure 2](#fig2){ref-type="fig"} A) ([@bib37]). Given that CAR is the uncoating receptor for all six serotypes of CV-B viruses ([@bib38]), we hypothesized that FcRn is also a universal uncoating receptor for other EV-B viruses. To test this hypothesis, we selected 11 echovirus serotypes in separate branches of the phylogenetic tree for further analysis: Echo 1, 3, 6, 7, 9, 11, 13, 14, 25, 26, and 30. EV-B85 and CVA-9 were also included because they are physiologically close to echoviruses ([Figures 2](#fig2){ref-type="fig"}A and 2B). For Echo 6 and 30, we tested both their epidemic and prototypic strains. *FCGRT* ^KO^ or *B2M* ^KO^ abolished the viral infection for EV-B85, CVA-9, and all of the above-mentioned echoviruses, suggesting that FcRn is a key host factor for these viruses ([Figure 2](#fig2){ref-type="fig"}B). In contrast, neither *FCGRT* ^KO^ nor *B2M* ^KO^ prevented CV-B4 or CV-B5 infections ([Figure 2](#fig2){ref-type="fig"}C). We thus propose that FcRn is the receptor candidate for the major group of EV-B viruses.Figure 2FcRn Is Essential for Major Serotypes of EV-Bs(A) Phylogenetic tree of all *Enterovirus B* serotypes. The representative serotypes proven to use FcRn as a receptor are shown in green, and the ones proven in previous works to use CAR as their uncoating receptor are shown in red. The remaining untested serotypes are shown in black.(B) Infection of 12 echoviruses, EV-B85 and CVA-9 in *FCGRT*^KO^, *B2M*^KO^, and WT HEK293T cells. TCID~50~ was calculated at 48 h.p.i.(C) Infection of CV-B4 and CV-B5 in *FCGRT*^KO^, *B2M*^KO^, and WT HEK293T cells. TCID~50~ was calculated at 48 h.p.i.The data depict means with SEM. Experiments were repeated three times. \# stands for undetected; ^∗∗∗∗^p \< 0.0001; ns, not significant.

Direct Binding of FcRn to EV-B Virus {#sec2.3}
------------------------------------

To verify if FcRn indeed serves as a receptor for and directly binds to EV-B viruses, we prepared the soluble extracellular domain of human FcRn protein and the extracellular domain of human CD55 protein ([Figure S3](#figs3){ref-type="fig"} ). Surface plasmon resonance (SPR) experiments were performed to examine the interaction between Echo 6 viral particles and these recombinant proteins. We found that FcRn bound to Echo 6 virions with an affinity of approximately 242 nM, similar to the positive control CD55 (375 nM, [Figures 3](#fig3){ref-type="fig"}A and 3B). In comparison, no binding was detected for either FcRn or CD55 to CV-B4, which uses CAR as its receptor ([Figures 3](#fig3){ref-type="fig"}C and 3D) ([@bib8]). ELISAs revealed dose-dependent binding of FcRn or CD55 to Echo 6 virions ([Figures 3](#fig3){ref-type="fig"}E and 3F). In comparison, CD26, the receptor for Middle East respiratory syndrome coronavirus (MERS-CoV), did not bind to Echo 6 ([Figure 3](#fig3){ref-type="fig"}G) ([@bib34]). To examine whether the soluble FcRn or CD55 protein could block virus infection, we incubated Echo 6 virus with FcRn, CD55, or CD26 protein at various concentrations prior to the infection and found that incubation with either FcRn or CD55 (but not CD26) led to infection inhibition in a dose-dependent manner ([Figure 3](#fig3){ref-type="fig"}H). These results suggest that FcRn is the receptor for Echo 6 virus.Figure S3FcRn and CD55 Soluble Protein Expression and Purification, Related to [Figure 3](#fig3){ref-type="fig"}(A) FcRn soluble protein was expressed by co-transfection of constructs encoding the FCGRT extracellular domain and B2M in HEK293T cells. The protein was eluted as a single peak from gel filtration on Superdex 200 column (GE Healthcare), and two bands showing FCGRT and B2M were evident by SDS-PAGE.(B) Gel filtration and SDS-PAGE of CD55 soluble protein purification.Figure 3Direct Binding of FcRn to Echo 6 Virus(A and B) BIAcore diagram of soluble FcRn protein (A) or CD55 protein (B) bound to Echo 6 virus. The K~D~ values were calculated by the BIAcore 3000 analysis software (BIAevaluation version 4.1).(C and D) The binding affinity of CV-B4 virus with FcRn (C) or CD55 protein (D) was measured by SPR, which served as a control.(E--G) Binding of FcRn (E), CD55 (F), or CD26 (G, control) in 2-fold serial dilutions with Echo 6 virus was assayed using ELISAs.(H) Dose dependence of soluble FcRn or CD55 protein to block Echo 6 virus infection. CD26 was used as a control protein.(I and J) Echo 6 was incubated with *FCGRT*^KO^, *B2M*^KO^, *CD55*^KO^, or WT HEK293T cells at 4°C for 1 h (I) or plus 37°C for 30 min (J). Cells were collected, and RNA was extracted for qPCR analysis.The data depict means with SEM. ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; ^∗∗∗∗^p \< 0.0001; ns, not significant.See also [Figures S3](#figs3){ref-type="fig"} and [S4](#figs4){ref-type="fig"}.

Next, we investigated the potential function of FcRn in EV-B entry. In contrast to CD55's role in facilitating echovirus attachment to the cell surface, FcRn did not seem to be involved in viral attachment because *FCGRT* ^KO^ or *B2M* ^KO^ had little effect on Echo 6 binding to the cell surface ([Figure 3](#fig3){ref-type="fig"}I). Viral internalization was reduced in both *FCGRT* ^KO^ and *B2M* ^KO^ cells ([Figure 3](#fig3){ref-type="fig"}J). However, substantial amounts of virus still entered the host cells in the absence of FcRn ([Figure 3](#fig3){ref-type="fig"}J). These results suggest that FcRn plays its essential role after viral attachment. Consistently, CD55 was mainly localized on the cell surface, whereas FcRn displayed substantial expression within the cytoplasm, presumably on the endosome membrane ([Figure S4](#figs4){ref-type="fig"} ).Figure S4Confocal Analysis of FcRn and CD55 Expressed in HEK293T and RD Cells, Related to [Figure 3](#fig3){ref-type="fig"}(A and C) Immunofluorescence staining of FcRn in HEK293T cells (A) and RD cells (C). FcRn is expressed both on the cell surface and in the cytoplasm.(B and D) Immunofluorescence staining of CD55 in HEK293T cells (B) and RD cells (D). CD55 was mostly expressed on the cell surface.

Structural Dissection of Echo 6 Virus with Its Receptors {#sec2.4}
--------------------------------------------------------

To elucidate the mechanism of FcRn in EV-B entry, we performed cryo-EM analysis to determine the structures of Echo 6 virus alone and in complex with CD55 or FcRn ([Figure 4](#fig4){ref-type="fig"} ). As enterovirus entry is mediated by endocytosis and the uncoating process occurs in the endosome, the structures were thus determined under both neutral (pH 7.4) and acidic (pH 5.5) conditions. With near-atomic or atomic resolutions, we obtained detailed characterization of the molecular events during Echo 6 entry ([Figure S5](#figs5){ref-type="fig"} ; [Table S3](#mmc3){ref-type="supplementary-material"}).Figure 4Cryo-EM Structures of the Echo 6 Viral Particle and Its Complex with Attachment (CD55) or Uncoating (FcRn) Receptor(A) The density maps of free Echo 6 full particles at pH 7.4 (2.9 Å) and pH 5.5 (3.4 Å).(B) The close-up view of the hydrophobic pocket and the "pocket factor" inside.(C and D) Cryo-EM maps (C) of Echo 6 virus in complex with CD55 at pH 7.4 (3.0 Å) and pH 5.5 (3.6 Å), as well as the close-up view (D) of the "pocket factor" with the receptor binding site shown in the same style as (B).(E--G) Cryo-EM maps (E) of Echo 6 virus in complex with FcRn at pH 7.4 (3.4 Å) and pH 5.5 (3.8 Å), as well as the close-up view showing the hydrophobic pocket of Echo 6 virus in complex with FcRn at pH 7.4 (F) and pH 5.5 (G). The receptor binding sites are shown in the same style as in (B) and (D).(H and I) Cryo-EM map of Echo 6 virus empty particle (H) at pH 7.4 (3.2 Å) and its collapsed pocket without "pocket factor" (I).All density maps are colored by radius as shown in the legend in (H). Atomic models of proteins are shown in ribbons and colored by chains with VP1, VP2, VP3, CD55, and FcRn heavy chain in green, cyan, magenta, blue, and orange, respectively. The "pocket factor" is shown in sticks, and the corresponding density map is shown at the 18σ contour level, which is highlighted by red ovals in close-up views. In the structures of the Echo 6 virus-FcRn complex at pH 5.5 and free Echo 6 virus empty particle, the pocket factor is absent, and its supposed positions are indicated by red dashed ovals.See also [Figures S5](#figs5){ref-type="fig"}, [S6](#figs6){ref-type="fig"}, and [Table S3](#mmc3){ref-type="supplementary-material"}.Figure S5Cryo-EM Analysis of Echo 6 Virus and Its Complex with Receptors, Related to [Figure 4](#fig4){ref-type="fig"}(A) Gold-standard Fourier shell correlation (FSC) curves of the structures of Echo 6 virus alone or in complex with its receptors. The 0.143 cut-off value is shown to indicate the resolution of each reconstruction.(B) Local resolution maps of representative density maps of Echo 6 virus or its complex with receptors. In all of these structures, most regions reach 3.0 Å and allowed the atomic details to be resolved.(C-K) Representative density maps and atomic models of the pocket region or receptor binding interface. Most side chains of key residues within the pocket are clearly resolved. The "pocket factor" is preserved in structures of free Echo 6 full-particle or in complex with CD55 at both pH 7.4 and pH 5.5. In the structures with FcRn binding, it is well accommodated at pH 7.4, but is released at pH 5.5.

Echo 6 virus is an icosahedral particle of ∼30 nm in diameter, in which the viral protein (VP)1, VP2, and VP3 form the outer shell, and VP4 is shielded underneath ([Figures 4](#fig4){ref-type="fig"}A and 4B). Each viral particle contains 60 copies of VP1, VP2, VP3, and VP4, which highly resembles the architecture of other enteroviruses ([@bib50]). Similar to other enteroviruses, the Echo 6 virus contains both full and empty particles (lacking the "pocket factor," VP4 subunit and genome inside) ([Figures 4](#fig4){ref-type="fig"}H and 4I). We found that only the full particles could bind the receptors, indicating that the empty particles are the relics of virus uncoating without infectivity. This is consistent with previous hypotheses based on EV71 studies ([@bib64]). Our biochemical studies and cell-based assays suggested that the role of FcRn in mediating Echo 6 entry is different from that of CD55, which enables virus attachment at the early stage of infection ([@bib46]). Based on these cryo-EM structures, binding of CD55 or FcRn at neutral pH did not induce evident conformational changes in the Echo 6 virions, in which the "pocket factor" is well accommodated ([Figures 4](#fig4){ref-type="fig"}C--4F). These observations indicated that both receptors can mediate virus attachment, and FcRn plays a role in inducing virus uncoating.

To further verify this, we examined the structures of Echo 6 virus in complex with either CD55 or FcRn at pH 5.5, which mimics the endosomal environment. The structure of CD55-bound Echo 6 virus at pH 5.5 was highly similar to that at pH 7.4. The "pocket factor" was still preserved, and the viral proteins did not exhibit significant structural rearrangements ([Figures 4](#fig4){ref-type="fig"}C and 4D). In contrast, the acidic condition caused dramatic changes to FcRn-bound Echo 6 viral particles. In this structure, the bound FcRn molecules began to dissociate from the virions, resulting in significantly reduced receptor densities due to low occupancies ([Figure 4](#fig4){ref-type="fig"}E). In comparison to the apo form and the CD55-bound Echo 6 virions, the "pocket factor" in FcRn-bound viral particles at pH 5.5 was released, and the pocket began to collapse with slight conformational changes on some residues within the "pocket" region ([Figures 4](#fig4){ref-type="fig"}G and [S6](#figs6){ref-type="fig"} ). Furthermore, the structure of the FcRn-Echo 6 complex under acidic conditions was also different from that of the empty viral particles. The pocket was not fully collapsed, and the VP4 subunits and viral genome inside were still preserved, suggesting that the FcRn-Echo 6 structure is an intermediate in the process of virus uncoating ([Figure S6](#figs6){ref-type="fig"}). This structural evidence demonstrates that FcRn mediates viral binding, "pocket factor" release, and capsid uncoating, whereas CD55 is solely responsible for the virus attachment.Figure S6Conformational Change Surrounding the "Pocket" of Echo 6 Virus and Echo 6 Virus with Its Receptor FcRn, Related to [Figure 4](#fig4){ref-type="fig"}(A) Backbone traces of atomic models showing the conformation of the "pocket" in Echo 6 full particles in pH 7.4. Backbone of Echo 6 full particles is shown in gray. The inner pocket is shown in surface model.(B) Conformational difference of the protein surrounding the "pocket" region of Echo 6 full-particle with empty-particle at pH 7.4. The backbone of Echo 6 full particle is shown in gray, and empty particle is shown in pink. The remarkable residues involved in conformational changes are shown as sticks and colored by elements. The pocket in the empty-particle is obviously collapsed as compared to that in the full viral particle.(C) Backbone traces of atomic models showing the conformation of the "pocket." Backbone of Echo 6 particle in the Echo 6-FcRn complex at pH 7.4 is shown in green. The pocket is highly similar to that in the full viral particle and allows the accommodation of the "pocket factor."(D) The conformational difference of the Echo 6-FcRn complex at pH 7.4 and pH 5.5. Backbones of the Echo 6 particle in the Echo 6-FcRn complex at pH 7.4 and pH 5.5 are shown in green and cyan, respectively. The "pocket" in the Echo 6-FcRn complex at pH 5.5 began to shrink compared to that at pH 7.4, but is not fully collapsed as observed in the empty particle. The remarkable residues involved in the conformational change are shown as sticks and colored by elements.

Molecular Interactions between Echo 6 Virus and Receptors {#sec2.5}
---------------------------------------------------------

FcRn binds to Echo 6 virus in its "canyon" site, with mainly the α2 and α3 helices in the α2 domain interacting with VP1, VP2, and VP3. VP1 dominates the interactions ([Figures 5](#fig5){ref-type="fig"}A and 5B). In contrast, CD55 binds across VP1 and VP2 outside of the "canyon," in which VP2 accounts for most of the interface ([Figures 5](#fig5){ref-type="fig"}C and 5D).Figure 5Molecular Interactions between Echo 6 Virus and FcRn/CD55 Receptors(A) The atomic model of Echo 6-FcRn in the main contacting interface. The viral proteins are shown in surface models, and the receptor is represented as ribbon model. VP1, VP2, and VP3 of Echo 6 are shown in green, cyan, and magenta, respectively. The interacting FCGRT subunit of FcRn is colored in orange. The "canyon" is indicated by a red asterisk.(B) The interaction details between Echo 6 virus and FcRn receptor. The proteins are colored by chains as in (A), and the contacting residues are shown as sticks and colored by elements. Hydrogen bonds are represented by black dashed lines.(C) The atomic model of the Echo 6-CD55 in the main contacting interface. The viral proteins (colored by chains) are shown in surface models, and CD55 (blue) is represented as ribbons. The interaction is mainly mediated by the SCR3 and SCR4 domains.(D) The interaction details between Echo 6 virus and CD55 in the same style of FcRn in (B).See also [Figure S7](#figs7){ref-type="fig"}.

The binding of FcRn to Echo 6 virus is mainly mediated by polar interactions with the α2 and α3 helices in the α2 domain, forming two interfaces on both sides of the canyon ([Figure 5](#fig5){ref-type="fig"}A). In the junction region of the α2 and α3 helices of FcRn, residues Q139, R140, Q143, and Q144 form consecutive hydrogen bond networks with VP1, VP2, and VP3 subunits, comprising the core of the FcRn-Echo 6 interface ([Figure 5](#fig5){ref-type="fig"}B). Two residues, D145 and K146, insert into the canyon site and form hydrogen bonds with Y75, D91, and Q99 of the VP1 subunit, which might be the key switch governing the transportation of the "pocket factor" ([Figure 5](#fig5){ref-type="fig"}B).

The interactions between CD55 and Echo 6 virus are mainly mediated by CD55's SCR3 and SCR4 domains ([Figure 5](#fig5){ref-type="fig"}C). In the terminal SCR4 domain, residue R214 forms a hydrogen bond with T154 of the VP2 subunit. Meanwhile, other residues within the 230-strand contact the VP2 subunit by extensive van der Waals interactions. Residue D240 in the SCR4 domain forms a center of interaction and contacts both the main chain and side chain of T163 in the VP2 subunit by three hydrogen bonds ([Figure 5](#fig5){ref-type="fig"}D). The SCR3 domain of CD55 interacts with both VP1 and VP2 subunits of Echo 6 virus. Residues S155 and S157 form two hydrogen bonds with K140 and N142 of the VP2 subunit, and Q141 connects Q204 of VP1 and N142 of VP2 by two consecutive hydrogen bonds. In addition, D143 interacts with G206 of VP1 in the periphery to further stabilize the interface ([Figure 5](#fig5){ref-type="fig"}D).

Because CD55 is a universal attachment receptor for several enteroviruses, we compared its binding sites on different viruses with the available virus-receptor complex structures ([@bib9], [@bib45], [@bib73]). Among them, the binding site of CD55 on Echo 6 virus is highly similar to that on CV-B3 but different from those on Echo 7 and Echo 12 viruses ([Figures S7](#figs7){ref-type="fig"} A and S7B). CD55 is rotated by ∼60° around the SCR3 domain on the Echo 7 and Echo 12 viruses and mainly binds to VP2 and VP3, leaving the "canyon" fully exposed ([Figure S7](#figs7){ref-type="fig"}B). As CD55 is not able to mediate uncoating of Echo 6 virus, it may dissociate from the virion before FcRn binding or bind to another icosahedral asymmetric unit as the canyon is shielded by CD55 to render steric hindrance for the access of FcRn ([Figure S7](#figs7){ref-type="fig"}C). For Echo 7 and Echo 12 viruses, however, the scenario is probably different as the two receptors could bind simultaneously within the same icosahedral asymmetric unit ([Figure S7](#figs7){ref-type="fig"}D).Figure S7Comprehensive Comparison of CD55 and FcRn Binding Sites on Different Enteroviruses, Related to [Figure 5](#fig5){ref-type="fig"}(A) Cartoon diagrams of CD55 bound to different enteroviruses determined by cryo-EM. Each component is represented with a unique color, and CD55 is colored in gold.(B) Superimposition of the atomic models of CD55 bound to different enteroviruses within an asymmetric unit. The icosahedral axes are shown as triangles and pentangles. The binding site of CD55 on Echo 6 virus is similar to that on CV-B3, but different from those on the Echo 7 and Echo 12 viruses. The "canyon" is indicated by a red asterisk.(C) Comparison of the binding sites of CD55 and FcRn on Echo 6 virus. The viral proteins are shown in surface models, and the receptors are shown as ribbons. The position of the "canyon" is indicated by a red asterisk. The steric clash between CD55 and FcRn is highlighted by a dashed oval.(D) Comparison of the binding sites of CD55 and FcRn on Echo 7 virus. The two receptors could bind simultaneously on the virus without clashing. Two different views of the superimposition are shown to reveal the compatibility of the two receptors in space.VP1, VP2 and VP3 of the virus are shown in green, cyan and magenta, respectively. CD55 molecules bound to Echo 6, Echo 7, Echo 12 and CV-B3 are shown in blue, black, pink and red, respectively. The FCGRT subunit of FcRn is shown in orange, and β2 m is in gray.

FcRn-Decorated Liposomes Induce Echo 6 Uncoating {#sec2.6}
------------------------------------------------

To further verify that FcRn-binding facilitates EV-B uncoating, we tested the FcRn-induced morphology changes of Echo 6 virions under 37°C, pH 5.5 conditions, which mimic the physiological conditions within the endosome ([Figure 6](#fig6){ref-type="fig"} ). Negative-stain EM analysis showed that binding of FcRn soluble protein triggered the aggregation of Echo 6 viral particles ([Figure 6](#fig6){ref-type="fig"}B). The same phenomenon was not observed in either free Echo 6 particles or the CD55-Echo 6 complex ([Figure 6](#fig6){ref-type="fig"}A). To further confirm that FcRn mediates virus capsid uncoating, a receptor-decorated liposome model was used as designed for a PVR-induced poliovirus uncoating study ([@bib20], [@bib62]). His-tagged FcRn or CD55 was incubated with nickel-charged liposomes to form receptor-decorated liposomes. Echo 6 particles attached to the surface of both FcRn- and CD55-decorated liposomes ([Figures 6](#fig6){ref-type="fig"}D and 6E) but not undecorated liposomes ([Figure 6](#fig6){ref-type="fig"}F). In addition, only the FcRn-decorated liposomes were able to induce structural transitions of Echo 6 particles ([Figure 6](#fig6){ref-type="fig"}E). A considerable proportion of empty particles were clearly observed after full Echo 6 particles were incubated with FcRn-decorated liposomes ([Figure 6](#fig6){ref-type="fig"}E). These data further demonstrate that FcRn is able to mediate EV-B uncoating under physiological conditions.Figure 6FcRn-Decorated Liposomes Induce Echo 6 UncoatingNegative staining EM detection of:(A) Purified Echo 6 full particles (upper left) and Echo 6-CD55 complexes.(B) Echo 6-FcRn complexes.(C) Nickel-charged liposomes.(D) Echo 6 incubated with CD55-decorated liposomes. Red arrows indicate the particles that attached to the surface of the liposomes.(E) Echo 6 incubated with FcRn-decorated liposomes. Green arrows indicate empty particles.(F) Echo 6 incubated with nickel-charged liposomes.All samples were treated for 10 min at 37°C, pH 5.5. The scale bar represents 100 nm.

Discussion {#sec3}
==========

Potential Mechanisms of Enterovirus Entry {#sec3.1}
-----------------------------------------

In this work, we identified FcRn as an uncoating receptor for echoviruses, CV-A9, and other physiologically closely related novel EV-B viruses. FcRn bound echovirus particles and induced conformational changes. FcRn-mediated Echo 6 capsid uncoating was confirmed with an FcRn-decorated liposome model, which mimics the physiological condition of FcRn-expressing endosomes. Our findings are consistent with previous reports that the binding of CD55 to echovirus does not induce conformational changes of the viral particles ([@bib24], [@bib45], [@bib46]). As FcRn is also present on the cell surface in addition to its expression on endosome membrane ([@bib49]), it is possible that CD55, as an initial attachment receptor, "hands off" the virus to FcRn on the cell membrane, which then mediates virus uncoating, just like CAR for CV-B entry ([@bib67]). It has been speculated by several groups that echoviruses should have an Ig-like receptor to mediate uncoating ([@bib45], [@bib46], [@bib50]). Moreover, β2 m has been found to play a crucial role for the infections of several echoviruses and CV-A9, but it is unclear how it works ([@bib25], [@bib36], [@bib66]). Our findings verify that β2 m plays an essential role for echovirus uncoating as a subunit of the FcRn receptor.

Most enteroviruses and some other picornaviruses use two different types of receptors at different stages of virus entry: an attachment receptor and an uncoating receptor ([@bib50], [@bib63], [@bib67]). Previous work has proposed functional differences between the attachment and uncoating receptors ([@bib46], [@bib50]). However, high-resolution structural evidence was missing to comprehensively understand the different functions of these receptors at the stage of virus entry. In addition, it has been suggested that uncoating receptor-mediated release of "pocket factor" allows picornavirus genome release into the cytosol, though more detailed evidence is required to better understand this process ([@bib50]). In this study, we unambiguously observed "pocket factor" release in the enterovirus at acidic pH after binding to the viral uncoating receptor, in high-resolution cryo-EM structures. Together with the cryo-EM structures at other stages of virus entry, we describe a working model for enterovirus entry ([Figure 7](#fig7){ref-type="fig"} ).Figure 7Model of Echovirus Entry into the CellThe four structural proteins (VP1, VP2, VP3, and VP4) comprising of viral capsid are indicated in blue, dark olive green, forest green, and pigment green, respectively. The viral RNA genome is shown in orange. CD55 and FcRn are displayed in light green and sky blue, respectively. The two undefined receptor binding modes on the viral surface are labeled with question marks.

Taking Echo 6 as an example, the virus binds to the attachment receptor CD55 on the cell surface, which triggers viral endocytosis and internalization. Viral particles are subsequently captured by the uncoating receptor FcRn within endosomes. The low pH environment of the endosomes prompts the extrusion of "pocket factor" after FcRn binding, resulting in virus uncoating and genome release. Alternatively, viral particles could also be captured by FcRn at the cell membrane, as FcRn bound at both neutral and acidic pH, and further induces endocytosis and uncoating in the endosome ([Figure 7](#fig7){ref-type="fig"}).

The Expression Distribution of FcRn Coincides with EV-B Tropism {#sec3.2}
---------------------------------------------------------------

It is known that FcRn facilitates the transport of maternal IgG across the placenta to the fetus and across the intestinal epithelium to the bloodstream of the newborn, as well as mediating the recycling of IgG for adults ([@bib49]). Our findings indicate that FcRn can be exploited by a large group of EV-B viruses for entry into the cell. There is substantial expression of FcRn in the gut, kidneys, lungs, placenta, hematopoietic cells, vascular endothelium, and at the blood-brain barrier ([@bib49], [@bib53]). This is in accordance with the tissue tropism of EV-B, as the gut is the major target for EV-B, where the viruses transmit to many other organs such as the CNS, liver, spleen, lungs, bone marrow, and heart to cause several types of diseases ([@bib14]). As functional receptor, FcRn possibly helps EV-B viruses cross both the blood-brain barrier and the blood-placenta barrier.

Implications for Antiviral Drug Design and Enterovirus-Based Oncolytic Therapeutics {#sec3.3}
-----------------------------------------------------------------------------------

Thus far, there is no approved drug or vaccine specifically against EV-B infection. Identification of FcRn as the functional receptor for a large group of EV-B viruses paves the way for effective vaccine and drug development. Most echoviruses and other physiologically closely related viruses in the EV-B group have no animal model, except for Echo 1 whose mouse model expresses human VLA-2 ([@bib17], [@bib28]). Lack of animal models greatly hinders studying the pathogenesis of EV-B as it relates to VE and VM, as well as the development of antiviral drugs and vaccines. Ectopic expression of CD55 is insufficient to make rodent cells susceptible to echovirus infection ([@bib47]). We now know why and could restore the echovirus susceptibility in rodent cells by expressing human FcRn, shedding light on the development of VE and VM animal models.

Further, echoviruses such as Echo 1, Echo 7, and Echo12 possess oncolytic activity ([@bib21], [@bib29], [@bib54], [@bib72]). RIGVIR, the Echo 7-based oncolytic drug, has been approved for clinical use in Latvia for melanoma treatment ([@bib15], [@bib18]). However, the lack of receptor information for Echo 7 hampered our understanding and evaluation of this type of oncolytic therapy ([@bib15], [@bib61]). The discovery of FcRn as its receptor will improve the development of echovirus-based oncolytic therapeutics.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Goat Anti-Mouse IgG H&L (Alexa Fluor® 488)AbcamCat\#ab150113; RRID: [AB_2576208](nif-antibody:AB_2576208){#interref155}Anti-FCGRT antibody - Extracellular domainAbcamCat\#ab193148; RRID: [AB_2801386](nif-antibody:AB_2801386){#interref160}Anti-CD55 antibodyAbcamCat\#ab33111; RRID: [AB_726605](nif-antibody:AB_726605){#interref165}Anti-CD55 antibodyAbcamCat\#ab133684; RRID: [AB_2801387](nif-antibody:AB_2801387){#interref170}Fluorescein-Conjugated Goat anti-Rabbit IgG (H+L)ZSGB-BIOCat\#ZF-0311; RRID: [AB_2571576](nif-antibody:AB_2571576){#interref175}FcRn-Specific AntibodyProteintechCat\#16190-1-AP; RRID: [AB_2231751](nif-antibody:AB_2231751){#interref180}Primary mouse monoclonal antibody against His tagZSGB-BIOCat\#TA-02; RRID: [AB_2801388](nif-antibody:AB_2801388){#interref185}Goat anti-rabbit IgG/HRPZSGB-BIOCat\#ZB-2301; RRID: [AB_2747412](nif-antibody:AB_2747412){#interref190}Goat anti-mouse IgG/HRPZSGB-BIOCat\#ZB-2305; RRID: [AB_2747415](nif-antibody:AB_2747415){#interref195}Anti- β2 m antibodybiorbytCat\#orb153541; RRID: [AB_2801389](nif-antibody:AB_2801389){#interref200}Anti-GAPDH antibodySanta CruzCat\#sc-47724; RRID: [AB_627678](nif-antibody:AB_627678){#interref205}Anti-GAPDH antibodycwbioCat\#CW0100M; RRID: [AB_2801390](nif-antibody:AB_2801390){#interref210}**Bacterial and Virus Strains**Echo 6-SJZ-366, GENBANK: MH830353Isolated from patient; [@bib13]N/AEcho 1-XZ2005-T48China CDCN/AEcho 3-GS08-072China CDCN/AEcho 4-XZ10-KA66China CDCN/AEcho 6-D'AmoriChina CDCN/AEcho 7-HN09-524China CDCN/AEcho 9-XZ99-120China CDCN/AEcho 11-SD03-478China CDCN/AEcho 13-2011-XJ-HT-YTH-63China CDCN/AEcho 14-GS09-522FChina CDCN/AEcho 16-XJ11-653128012China CDCN/AEcho 25-GS10-142TChina CDCN/AEcho 26-2006-X122China CDCN/AEcho 30-YN2016-AB6China CDCN/AEcho 30-BastinniChina CDCN/AEV-B85-XJ2011-3-29China CDCN/ACV-A9-HB10-221China CDCN/ACV-B4-NM07-714China CDCN/ACV-B5-SJZ-097China CDCN/A**Chemicals, Peptides, and Recombinant Proteins**DMEM basicThermo Fisher ScientificCat\#C11995500BTFBSInvitrogenCat\#16000044Lipofectamine 2000InvitrogenCat\#11668019XtremeGENE HP DNA transfection reagentRocheCat\#06366546001SucroseSigmaCat\#V900116-500 gFixation/Permeabilization Solution KitBDCat\#554722Human protein CD26[@bib34]N/AHuman FcRn soluble protein, GENBANK: [NM_001136019.2](ncbi-n:NM_001136019.2){#intref0010} and [NM_004048](ncbi-n:NM_004048){#intref0015}This paperN/AHuman CD55 soluble protein GENBANK: NM_000574.3This paperN/A**Critical Commercial Assays**HisTrap HP 5 ml columnGE HealthcareCat\#17524802Hiload 16/600 Superdex 200 PG columnGE HealthcareCat\#28989335Membrane concentratorMilliporeCat\#UFC9010961Series S Sensor Chip CM5GE HealthcareCat\#29149603**Deposited Data**Cryo-EM Echovirus 6 bound to FcRn (pH 7.4)This paperEMDB-9687, PDB: [6ILM](pdb:6ILM){#intref0020}Cryo-EM Echovirus 6 bound to FcRn (pH 5.5)This paperEMDB-9686, PDB: [6ILL](pdb:6ILL){#intref0025}Cryo-EM Echovirus 6 full particle (pH7.4)This paperEMDB-9690, PDB: [6ILP](pdb:6ILP){#intref0030}Cryo-EM Echovirus 6 empty particle (pH7.4)This paperEMDB-9689, PDB: [6ILO](pdb:6ILO){#intref0035}Cryo-EM Echovirus 6 full particle (pH5.5)This paperEMDB-9688, PDB: [6ILN](pdb:6ILN){#intref0040}Cryo-EM Echovirus 6 bound to CD55 (pH 7.4)This paperEMDB-9685, PDB: [6ILK](pdb:6ILK){#intref0045}Cryo-EM Echovirus 6 bound to CD55 (pH 5.5)This paperEMDB-9684, PDB: [6ILJ](pdb:6ILJ){#intref0050}**Experimental Models: Cell Lines**Human: HEK293TATCCATCC CRL-3216Human: rhabdomyosarcoma (RD) cellsATCCATCC CCL-136Hamster: Chinese hamster ovary (CHO-K1) cellsATCCATCC CCL-61Hamster: baby hamster kidney (BHK-21) cellsATCCATCC CCL-10Human: HEK293T FCGRT^KO^EdigeneCat\#CL0029124702AHuman: HEK293T B2M^KO^EdigeneCat\#CL0049664423AHuman: HEK293T CD55^KO^This paperN/A**Oligonucleotides**Primers: CaslibF: TATCTTGTGGAAAGGACGAAACACC;\
CaslibR: AATACGGTTATCCACGCGGC[@bib77]N/AsgRNA sequence: for CD55 KO: GTTCTCTTCTGT\
AACCTGGAThis paperN/APrimers: for CD55 KO detection: CD55_1F: TTTAGGTAGC\
TGCGAGGTGC, CD55_1R: ATTTCCCCCAAACACCAGA\
TG; CD55_2F: TGCATCCCTCAAACAGCCTT, CD55_2R:\
CCCAAACACCAGATGGTTGAAA; CD55_3F: GCAGGA\
CATTAGTCCAGGGG, CD55_3R: CCCCAAACACCAGA\
TGGTTGAAThis paperN/AOligonucleotides used for the membrane protein sgRNA library constructionThis paper[Table S1](#mmc1){ref-type="supplementary-material"}**Recombinant DNA***p*MD2.GLaboratory of Didier TronoAddgene \#12259*p*CMVR8.74Laboratory of Didier TronoAddgene \#22036lentiCas9-Blast[@bib51]Addgene \#52962*p*LVX-IRES-ZsGreen1ClontechCat\#632187*p*Lenti-MCS-BSD[@bib77]N/A*p*LVX-DsRed-Monomer-N1ClonetechCat\#632152*p*LVX-IRES-ZsGreen1-FCGRTThis paperN/A*p*Lenti-MCS-BSD-B2MThis paperN/A*p*LVX- Monomer-N1-CD55This paperN/ABeta-2 microglobulin cDNA ORF Clone, Human, N-His tagSino biologicalCat\# HG11976-NH*p*CMV3-FCGRTThis paperN/A*p*CMV3-CD55This paperN/A**Software and Algorithms**Model-based Analysis of Genomewide CRISPR/Cas9 Knockout (MAGeCK)[@bib33]<https://sourceforge.net/p/mageck/wiki/Home>TIDE[@bib10]<https://tide.nki.nl/>MEGA program (version 5.0)[@bib59]N/ABIAcore 3000 Evaluation softwareGE HealthcareN/AGraphpad Prism 6GraphPad Software<https://www.graphpad.com/scientificsoftware/prism/>Flowjo 7.6.1FLOWJO<https://www.flowjo.com/solutions/flowjo/downloads>MotionCor2[@bib76]N/ACTFFIND4[@bib48]N/AEMAN2[@bib60]N/ARelion-2.0[@bib52]N/APyMOL softwareDeLano WL PyMOL molecular graphics system<https://pymol.org/2/>Chimera[@bib44]N/ACoot[@bib19]<https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/>Phenix[@bib3]<http://www.phenix-online.org/>MolProbity[@bib12]N/Ae2boxer.py[@bib60]N/A

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, George F. Gao (<gaof@im.ac.cn>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Cells and viruses {#sec4.3.1}

Human rhabdomyosarcoma (RD) cells, HEK293T, Chinese hamster ovary (CHO) cells and baby hamster kidney (BHK) cells were maintained in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum (FBS, Invitrogen) and 100 U/mL of penicillin-streptomycin with 5% CO~2~ at 37°C.

Viruses used in this work include: Echo 1 (XZ2005-T48), Echo 3 (GS08-072), Echo 6 (strains SJZ-366 and D'Amori), Echo 7 (HN09-524), Echo 9 (XZ99-120), Echo 11 (SD03-478), Echo 13 (2011-XJ-HT-YTH-63), Echo 14 (GS09-522F), Echo 25 (GS10-142T), Echo 26 (2006-X122), Echo 30 (strains YN2016-AB6 and Bastinni), EV-B85 (XJ2011-3-29), CV-A9 (HB10-221), CV-B4 (NM07-714) and CV-B5 (SJZ-097). All viruses were propagated on RD cells. The anti-Echo 6 sera production in mice was performed according to the procedures approved by the Chinese Academy of Sciences and comply with all relevant ethical regulations regarding animal research.

Method Details {#sec4.4}
--------------

### Construction of the Cas9/sgRNA library {#sec4.4.1}

We constructed a focused Cas9/sgRNA library targeting 3,283 genes encoding human membrane proteins. This library consisted of 30,848 sgRNAs, among which 400 were non-targeting sgRNAs as negative controls. The sgRNA plasmid library was packaged in HEK293T cells after co-transfection with *p*MD2.G, a plasmid expressing vesicular stomatitis virus glycoprotein (VSV-G), and *p*CMVR8.74, a lentiviral packaging plasmid (Addgene), with the X-tremeGENE HP DNA transfection reagent (Roche). Supernatants were collected and filtered with a syringe filter with a 0.22 μm pore size.

A single clone of RD cells stably expressing *S. pyogenes* cas9 (SpCas9) was constructed by transduction of a lentiviral vector expressing spCas9 and selection by blasticidin (Addgene \#52962) ([@bib51]). The cleavage activity of Cas9 nuclease in this cell line was confirmed by T7E1 assays. RD-Cas9 cells were transduced with the packaged lentiviral sgRNA library at a multiplicity of infection (MOI) of 0.3, followed by a puromycin selection for ∼2 weeks ([@bib43], [@bib79]).

### CRISPR-Cas9 screening and data analysis {#sec4.4.2}

Echo 6 strain SJZ-366 (MOI of 0.01) was introduced onto approximately 10^8^ RD-Cas9 cells harboring the sgRNA library in DMEM with 2% FBS. After 24 h, \> 99% cells were detached, with cytopathic effect (CPE) observed. The medium was exchanged for fresh DMEM with 2% FBS at 24 h and 48 h.p.i (hours post inoculation). The medium was then exchanged with 10% FBS-supplemented DMEM for the resistant cells to grow at day 4 post infection. The medium was exchanged with fresh 10% DMEM every 2 days, and surviving cells were passed into a 6-well plate. Cell populations were further expanded to reach ∼10^7^, and genomic DNA was extracted. The sgRNA-coding regions within the genomic DNA from both experimental groups (two biological replicates) and untreated cell libraries (two biological replicates) were amplified by PCR (CaslibF primer: TATCTTGTGGAAAGGACGAAACACC; CaslibR primer: AATACGGTTA TCCACGCGGC) and subsequently identified by deep-sequencing analysis. The screening data were analyzed with the published Model-based Analysis of Genome-wide CRISPR/Cas9 Knockout (MAGeCK) method ([@bib33]). sgRNAs with low read-counts (≤10) in both control libraries were excluded from data analysis.

### KO cell line establishment and validation {#sec4.4.3}

Both *FCGRT* ^KO^ and *B2M* ^KO^ cell lines were ordered from Edigene, Beijing. The HEK293T CD55^KO^ cell line was constructed by transient co-transfection of a plasmid expressing sgRNA targeting the *CD55* gene and a plasmid expressing spCas9. The sgRNA sequence was GTTCTCTTCTGTAACCTGGA. After selection with puromycin for ∼2 weeks, single cells were seeded in 96-well plates. After cell expansion, the cell clones in each well were transferred to 12-well plates for further culture. The cell clones were screened for CD55 expression by western blot analysis, and the clones lacking CD55 expression were selected. The CD55 DNA fragments of target loci were independently amplified by PCR with three primer pairs (CD55_1F: TTTAGGTAGCTGCGAGGTGC and CD55_1R: ATTTCCCCCAAACACCAGA TG; CD55_2F: TGCATCCCTCAAACAGCCTT and CD55_2R: CCCAAACACCA GATGGTTGAAA; and CD55_3F: GCAGGACATTAGTCCAGGGG and CD55_3R: CCCCAAACACCAGATGGTTGAA). The purified PCR products were sequenced (Ruibiotech, Beijing), and the insertions and deletions (indels) within the *CD55* gene caused by sgRNA/Cas9 were analyzed with an online tool (<https://tide.nki.nl/>) ([@bib10]).

### Viral TCID~50~ analysis in KO cell lines {#sec4.4.4}

Enteroviruses were propagated in RD cells and collected when \> 80% CPE was observed. Serially diluted viruses (from 10^−1^- 10^−10^) were inoculated onto WT and KO HEK293T cells. CPE was observed at 48 h.p.i., and TCID~50~ was calculated using the Reed-Muench method.

### Plasmid construction and lentivirus generation {#sec4.4.5}

The C-terminally FLAG-tagged human FCGRT coding sequence with a human IL2 signal sequence was cloned into the EcoRI and BamHI sites of the *p*LVX-IRES-ZsGreen1 vector (Clontech, 632187). The N-terminally His-tagged human β2 m coding sequence with a human IL2 signal sequence was cloned into the *Xba*I and *Mlu*I sites of *p*Lenti-MCS-BSD ([@bib77]). C-terminally HA-tagged human CD55 with a human IL2 signal sequence was cloned into the EcoRI and *Xba*I sites of *p*LVX-DsRed-Monomer-N1 (Clontech, 632152) with a puromycin-resistant element. Lentiviruses were packaged in HEK293T cells by co-transfection of each of the above-mentioned plasmid with *p*LP1, *p*LP2 and VSV-g (Invitrogen) at a ratio of 20:20:13:5 using Lipofectamine 2000 (Invitrogen, 11668019).

### Trans-complementation {#sec4.4.6}

The packaged lentiviruses were introduced into corresponding KO cell lines. HEK293T *FCGRT* ^KO^ +Lenti-FCGRT cells were sorted by flow cytometry. *B2M* ^KO^ +Lenti-B2M cells were selected with 5 μg/mL blasticidin for 7 days. *FCGRT* ^KO^ +Lenti-GFP and *B2M* ^KO^ +Lenti-GFP were used as controls. WT, *FCGRT* ^KO^/ *B2M* ^KO^ cells, *FCGRT* ^KO^ +Lenti-FCGRT/ *B2M* ^KO^ +Lenti-B2M and *FCGRT* ^KO^ +Lenti-GFP/ *B2M* ^KO^ +Lenti-GFP were seeded in 12-well plates. The Echo 6 strain SJZ-366 (MOI 0.01) was inoculated onto these cells, and supernatants were collected for TCID~50~ and qPCR analyses after 24 h. TCID~50~ assays were performed on RD cells. Viral RNA from supernatants was extracted for qPCR analysis (qPCR primers: PEVF, CCTGAATGCGGCTAATCC and PEVR; TTGTCACCATWAGCAGYCA PEV Probe, FAM-CCGACTACTTTGGGWGTCCGTGT-TAMRA).

### Ectopic expression {#sec4.4.7}

After seeding in 12-well plates, CHO and BHK cells were transduced with Lenti-FCGRT + Lenti-B2M, Lenti-CD55, Lenti-FCGRT + Lenti-B2M+ Lenti-CD55, or Lenti-GFP. Positive cells were selected with antibiotics and/or flow cytometry sorting (Lenti-FCGRT positive: FITC positive in flow cytometry; Lenti-B2M positive: 5 μg/mL blasticidin selection for 7 days; and Lenti-CD55 positive: 5 μg/mL puromycin selection for 7 days). Echo 6 strain SJZ-366 (MOI of 0.1) was inoculated into the cells for 1 h, then removed and washed twice with PBS. Supernatants were collected for TCID~50~ and qPCR analyses 24 h.p.i.

### Growth curve analysis {#sec4.4.8}

*FCGRT* ^KO^, *B2M* ^KO^, *CD55* ^KO^ and WT HEK293T cells were seeded in 12-well plates. Echo 6 strain SJZ-366 (MOI 0.01) was added to these cells, and supernatants were collected at 0, 12, 24, 48 and 60 h.p.i. Viral RNA was extracted for qPCR analysis.

### Phylogenic analysis {#sec4.4.9}

Pairwise alignment of the nucleotide sequences of EV-B was performed using the MEGA program (version 5.0) ([@bib59]). Phylogenetic trees were constructed by the maximum likelihood algorithms implemented in the MEGA program using the Tamura-Nei model. Regions containing alignment gaps were omitted from the analysis. The branch lengths of the dendrogram were determined from the topologies of the trees and were obtained by majority rule consensus among 1000 bootstrap replicates. Bootstrap values \> 80% were considered statistically significant for grouping. The output tree files were visualized using the FigureTree program.

### Bright light image of CPE {#sec4.4.10}

For light images, *FCGRT* ^KO^, *B2M* ^KO^, CD55^KO^ and WT HEK293T cells were infected with Echo 6 at a MOI of 1. Twenty-four hours later, CPE was observed, and pictures were taken.

### Echo 6 antibody generation {#sec4.4.11}

Echo 6 was inactivated by 0.05% β-propiolactone at 4°C for 48 h, and β-propiolactone was then inactivated at 37°C for 2 h. Eight-week-old BALB/c mice were intramuscularly immunized with 200 μL inactivated Echo 6. After boosting twice, sera were collected, and IgG was purified with a protein A column (GE Healthcare).

### Immunofluorescence {#sec4.4.12}

For immunofluorescence analysis of Echo 6 infection, *FCGRT* ^KO^, *B2M* ^KO^, CD55^KO^ and WT HEK293T cells were seeded onto coverslips in 24-well plates at a density of 10,000 cells per well overnight and infected by Echo 6 (MOI 10). Eight hours later, cells were fixed with 4% paraformaldehyde for 30 min and permeabilized with 0.2% Triton X-100 in PBS for 20 min. After blocking with 3% BSA, cells were incubated for 1 h with anti-Echo 6 primary antibody at a dilution of 1:200, followed by incubation with an Alex 488-labeled secondary antibody (Abcam, ab150113, 1:100 dilution). After DAPI staining for 1 h, samples were mounted on microscope slides. Images were taken with a Leica TCS-SP confocal microscope and processed using ZEN software.

For FcRn and CD55 staining, cells were stained by anti-FCGRT (Abcam, ab193148) or anti-CD55 (Abcam, ab33111) primary antibody at a dilution of 1:100. FITC-labeled anti-rabbit secondary antibody (ZSGB-BIO, ZF-0311, 1:100 dilution) and Alex 488-labeled anti-mouse secondary antibody (Abcam, ab150113, 1:100 dilution) were subsequently used, respectively.

### Gene cloning, expression, and protein purification {#sec4.4.13}

The human FCGRT coding fragment (A16--L282) or the human CD55 coding fragment (D35-G285) was inserted into *p*CMV3 (Sino biological, China) with a human IL2 signal sequence at the N terminus and six histidines at the C terminus using the HindIII and BamHI sites, respectively. Plasmids expressing human FCGRT and human β2 m were transiently co-transfected into HEK293T cells for human FcRn protein expression. Plasmid expressing human CD55 was transfected into HEK293T cells for CD55 expression. In each case, the supernatant was collected, and the protein was subsequently purified by Ni-nitrilotriacetic acid (NTA) chromatography (GE Healthcare) and gel filtration using a Hiload 16/600 Superdex 200 PG column (GE Healthcare) with a buffer containing 20 mM Tris·HCl and 150 mM NaCl (pH 8.0).

### Virus purification {#sec4.4.14}

Echo 6 strain SJZ-366 was propagated in RD cells for 36 h at 37°C after inoculation with a MOI of ∼0.1. The supernatant was collected and centrifuged at 12,000 x g for 60 min to remove cell debris. Initial purification was performed by ultracentrifugation through a 30% (w/v) sucrose cushion using a type 45Ti rotor at 140,000 x g for 2 h. The virus was resuspended in PBS (phosphate buffer saline, pH 7.4) and loaded onto a sucrose gradient (7.5%--45%, w/v) for further purification by centrifugation using a SW41 rotor at 4°C for 5 h. Fractions containing viral particles were pooled and buffer-exchanged into PBS buffer and concentrated using an Amicon Ultra-6 100 kDa cut-off centrifugal concentrator (Millipore).

### SPR {#sec4.4.15}

SPR binding experiments were performed using an BIAcore 3000 device (GE Healthcare) at room temperature (25°C) to measure the kinetics and affinity of FcRn or CD55 binding to Echo 6 virus. The buffers for all proteins used for kinetic analyses were exchanged to PBST consisting of PBS and 0.005% (v/v) Tween-20 (pH 7.4) via gel filtration. Purified Echo 6 or CV-B4 viruses were immobilized on a CM5 chip with the Standard EDC/NHS coupling method to about 6,000 response units (RU). Serial dilutions of FcRn or CD55 were prepared and sequentially injected at a rate of 30 μL/min, and the data were collected over time. After each cycle, a short injection of 4 M NaCl was employed to regenerate the sensor surface. The binding kinetics was analyzed, and affinity constants were calculated using BIAcore 3000 analysis software (BIAevaluation Version 4.1).

### ELISA-based binding assay {#sec4.4.16}

The binding of FcRn or CD55 to Echo 6 virions was determined by ELISAs. The purified virions were immobilized at 1.5 × 10^10^ TCID~50~/well in carbonate-bicarbonate buffer (pH 9.6) on 96-well plates at 4°C overnight. Then, wells were washed with PBS-T (0.01 M PBS with 0.1% (v/v) Tween 20) for 5 × 5 min. After blocking with 5% non-fat milk at room temperature (RT) for 1 h, plates were washed once with PBS-T (0.01 M PBS with 0.1% (v/v) Tween 20). FcRn, CD55, or the irrelevant human protein CD26 ([@bib34]) was serially diluted in PBS and then added and incubated at RT for 1 h. The wells were washed with PBST for 5 × 5 min. After that, anti-FcRn (Proteintech, 16190-1-AP) or anti-His (ZSGB-BIO, TA-02) antibodies were diluted with PBS and added to the wells for 1 h at RT. The plates were washed with PBST for 5 × 5 min. Subsequently, goat anti-rabbit IgG/HRP (ZSGB-BIO, ZB-2301) or goat anti-mouse IgG/HRP (ZSGB-BIO, ZB-2305) diluted with PBS to 1:2000 was added and incubated at RT for 1 h, followed by washing with PBST for 5 × 5 min. TMB (3, 3′, 5′, 113 5′- tetramethylbenzidine) substrate (CWBio) was added, and 2 M HCl was applied to stop the reaction. Absorbance at 450 nm was measured and recorded.

### Blocking assays with FcRn or CD55 soluble protein {#sec4.4.17}

RD cells were seeded into 48-well plates. Serial dilutions of purified FcRn or CD55 soluble protein were incubated with Echo 6 (0.1 MOI) for 2 h at 4°C in a volume of 100 μL. The mixture was then added to RD cells for 1 h incubation at 37°C, removed, and washed twice with PBS. DMEM with 2% FBS was added to the cells and incubated for another 12 h. Supernatants were collected for viral RNA extraction and qPCR analysis.

### Virus binding and internalization assays {#sec4.4.18}

The assays were performed in suspension as described previously ([@bib75]) with modifications. Briefly, *FCGRT* ^KO^, *B2M* ^KO^, CD55^KO^, and WT HEK293T cells were collected in suspension. Echo 6 strain SJZ-366 (MOI 50) was incubated with the cells (1 × 10^6^) on ice for 1 h. After three cycles of washing using ice-cold PBS, cells were collected, and RNAs were extracted for qPCR analysis. For the internalization assays, after on-ice incubation, the cell-virus mixture was directly placed at 37°C for 30 min. Cells were washed once with PBS and then treated with 500 ng/mL proteinase K on ice for 1 h. After three washes, cells were collected for RNA extraction and qPCR analysis. Virus titers were detected using PEV primers and probes as described above. GAPDH was included as an internal control (qPCR Primers: HGapdhF, CCACTCCTCCACCTTTGAC and HGapdhR, ACCCTGTTGCT GTAGCCA; and HGapdhProbe, FAM- TTGCCCTCAACGACCACTTTGTC-TAMRA)

### Cryo-EM sample preparation and data collection {#sec4.4.19}

To prepare the Echo 6-CD55/FcRn complexes, purified Echo 6 particles (1.8 mg/mL) were incubated with excess CD55/FcRn protein for 8 h and 10 min at 4°C, respectively. A 3 μL aliquot of free-Echo6 virus, Echo6-CD55, or Echo6-FcRn complex at pH 7.4 was placed on freshly glow-discharged copper grid coated with a layer of ultra-thin carbon film. After a 30 s incubation for particle absorption, the excess buffer solution was manually blotted, and the grid was plunge-frozen using a Vitrobot Mark IV operated at 100% humidity. For the low pH samples, a drop (4 μL) of acidic buffer (20 mM MES and 150 mM NaCl, pH 5.5) was immediately added to the grid after the first blotting, the samples were incubated for an additional 10 min at 4°C before blotting and plunge-freezing.

Cryo-EM data was manually collected using a 300 kV Titan Krios (FEI) microscope equipped with a K2 summit camera. Images were recorded in super-resolution counting mode with a calibrated pixel size of 1.35 Å. Each exposure was performed with an accumulative dose of 40 e^-^/Å^2^, which was fractionated into 32 frames for each image stack. The final defocus range of the micrographs was −1.0 to −3.0 μm.

### Image processing {#sec4.4.20}

The movie-frames were aligned and summed using the program MotionCor2 ([@bib76]). The initial contrast transfer function (CTF) parameters were estimated with CTFFIND4 ([@bib48]), and particles were semi-automatically boxed using the e2boxer.py tool in the EMAN2 ([@bib60]) program package. Seven structures were determined using Relion-2.0 ([@bib52]) with icosahedral symmetry applied. Under physiological conditions (pH 7.4), the structures of free-Echo 6 full and empty particles, Echo 6-CD55 complex, and Echo 6-FcRn complex were determined at 2.9, 3.2, 3.0, and 3.4 Å resolution, respectively. Under acidic conditions (pH 5.5), the structures of free-Echo6 full particle, Echo 6-CD55, and Echo 6-FcRn complexes were determined at 3.4, 3.6, and 3.8 Å resolution, respectively. The resolutions were estimated by the gold-standard Fourier shell correction 0.143 cut-off values ([@bib52]).

### Model building and refinement {#sec4.4.21}

The crystal structure of Echovirus 1 (PDB: [1EV1](pdb:1EV1){#intref0100}) was used as the initial model to fit the free-Echo 6 density map (pH 7.4, 2.9 Å) using Chimera ([@bib44]). After initial fitting, the model was manually adjusted in Coot ([@bib19]) to improve map fitting and update the sequence registers. The density map of an asymmetric unit (ASU) was then segmented using Chimera ([@bib44]) and placed into a pseudo crystallographic unit cell (P1 space group) for model refinement. The atomic model was refined against the ASU map in real space using Phenix with secondary structure restraints applied. Model statistics (including bond lengths, bond angles, and all-atom clash), rotamer statistics, and Ramachandran plot statistics were monitored during the refinement procedure. After several rounds of iterative model building and refinement, the model coordinates converged and fit well in the density map by visual inspection. At this point, the individual B factors and occupancies of each atom were refined using the standard reciprocal space refinement procedure in Phenix ([@bib3]) The stereochemical quality of the final model was assessed using MolProbity ([@bib12]). The Echo 6-CD55/FcRn complexes were modeled with the free-Echo6 structure as the initial model following a similar procedure as described above. All data collection, processing, model building and refinement statistics are summarized in [Table S3](#mmc3){ref-type="supplementary-material"}.

### Structure analysis and visualization {#sec4.4.22}

The reconstructed maps and atomic models were visualized using Chimera ([@bib44]) and analyzed using the wrapped applications. All EM density figures were rendered by Chimera, and cartoon representations of atomic models were generated with PyMOL software (DeLano WL PyMOL molecular graphics system. Available from: URL: <http://www.pymol.org>).

### Preparation of receptor-decorated liposomes {#sec4.4.23}

Liposomes consisting of phosphatidylethanolamine, phosphatidylcholine, sphingomyelin, cholesterol, and phosphatidic acid were supplied in chloroform and mixed in molar ratios of 1:1:1:1.5:0.3, respectively ([@bib57]). Nickel-chelating liposomes, for binding of the His-tagged receptor, were generated by the inclusion of the nickel salt of 1,2-dioleoyl-sn-glycero-3-{\[N(5-amino-1-carboxypentyl) iminodiacetic acid\] succinyl}, at a final concentration of 20% (w/w). The chloroform was evaporated under argon gas to produce a lipid film, which was dried under vacuum overnight. Dried lipid was rehydrated at a concentration of 3 mg/mL in 50 mM HEPES (pH 7.3) and 50 mM NaCl. The nickel-chelating liposomes were made by extruding lipids through a membrane filter with 0.4-μm diameter pores and then incubated with His-tagged CD55 or FcRn at a final concentration of 100 μg/mL at room temperature for 30 min.

### Incubation assay of receptor-decorated liposomes with Echo 6 particles {#sec4.4.24}

High-purity full-Echo 6 particles were obtained by 15%--45% (w/v) sucrose density gradient centrifugation. Receptor-decorated liposomes and full-Echo 6 particles were separately and rapidly buffer-exchanged and concentrated using an Amicon Ultra-6 100 kDa cutoff centrifugal concentrator into acidic buffer (20 mM MES and 150 mM NaCl, pH 5.5) at 4°C. Samples of receptor-decorated liposomes containing approximately 2 mg/mL lipid and 0.3 mg/mL bovine serum albumin (BSA) were mixed at 37°C with equal volume (100 μL) of full-Echo 6 particles (0.8 mg/mL). After a 10-min incubation, the mixed samples were used for negative staining. The specimens were loaded onto an FEI Tecnai G20 transmission electron microscope operating at 120 kV for imaging.

### Western blotting {#sec4.4.25}

Cells were collected, lysed, and electrophoresed using 12% SDS-PAGE. Proteins were transferred onto nitrocellulose membranes. The membranes were blocked with 5% non-fat milk for 2 h at 4°C, then stained at 4°C overnight using the following primary antibodies: anti-FcRn (Proteintech, 16190-1-AP), anti-CD55 (Abcam, ab133684), anti- β2 m (biorbyt, orb153541) and anti-GAPDH (Santa Cruz, sc-47724; cwbio, CW0100M). After three washes with PBST (PBS with 0.1% Tween-20), the membranes were incubated with secondary antibody (goat anti-mouse IgG/HRP (ZSGB-BIO, ZB-2305) or goat anti-rabbit IgG/HRP (ZSGB-BIO, ZB-2301)) for 1 h at RT. After another set of washes, the blots were analyzed using SuperSignal West Pico Chemiluminescent Substrate (Life Technologies).

### Flow cytometry {#sec4.4.26}

Cells were washed with PBS, trypsinized, and pelleted. For fixed cell staining, cells were fixed using a Fixation/Permeabilization Solution Kit (BD, 554722) for 20 min at 4°C and washed twice with PBS. For cell surface staining, cells were washed and directly sent for primary antibody staining. The cells were stained with CD55 (Abcam, ab33111) or isotype antibody at a dilution of 1:100, followed by three washes with PBS, and incubated with an Alex 488 labeled secondary antibody (Abcam, ab150113, 1:100 dilution) for 1 h. Flow cytometry acquisition was performed with a BD FACSDiva-driven BD FACSCANTO I. Data were analyzed with FlowJo software.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Statistical significance was determined as p \< 0.05 using GraphPad Prism 6. Experiments were analyzed by unpaired two-tailed t tests with the Welch post-correction or ANOVA with multiple comparisons.

Data and Software Availability {#sec4.6}
------------------------------

### Data Resources {#sec4.6.1}

The cryo-EM density maps and corresponding atomic coordinates have been deposited in the Electron Microscopy Data Bank (EMDB) and Protein Data Bank (PDB), respectively. The accession numbers for the cryo-EM structures reported in this paper are: Echovirus 6 full particle at pH7.4 (EMDB-9690, PDB: [6ILP](pdb:6ILP){#intref0110}); Echovirus 6 empty particle at pH7.4 (EMDB-9689, PDB: [6ILO](pdb:6ILO){#intref0115}); Echovirus 6 full particle at pH5.5 (EMDB-9688, PDB: [6ILN](pdb:6ILN){#intref0120}); Echovirus 6 bound to CD55 at pH 7.4 (EMDB-9685, PDB: [6ILK](pdb:6ILK){#intref0125}); Echovirus 6 bound to CD55 at pH 5.5 (EMDB-9684, PDB: [6ILJ](pdb:6ILJ){#intref0130}); Echovirus 6 bound to FcRn at pH 7.4 (EMDB-9687, PDB: [6ILM](pdb:6ILM){#intref0135}); Echovirus 6 bound to FcRn at pH 5.5 (EMDB-9686, PDB: [6ILL](pdb:6ILL){#intref0140}).
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